乳腺癌组织中ER、PR、Ps2、C-erbB-2表达与新辅助化疗疗效的关系  

Relationship between expression of ER,PR,Ps2,Her-2 and neoadjuvant chemotherapy effect in breast cancer

作　　者：杨科[1] 崔树德[1] 李连方[1] 

机构地区：[1]郑州大学基础医学院,郑州450000

出　　处：《山东医药》2011年第6期18-19,共2页Shandong Medical Journal

摘　　要：目的探讨乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)、雌激素调节蛋白(Ps2)和C-erbB-2的表达与新辅助化疗(NACT)疗效的关系。方法采用免疫组化法检测50例接受NACT的乳腺癌患者化疗前的ER、PR、Ps2、C-erbB-2,并分析其与新辅助化疗效果的关系。结果 ER阳性和PR阳性者NACT有效率分别为59.4%和60.6%,明显低于ER阴性者的83.3%和PR阴性者的82.4%(P均<0.05),Ps2阳性者与Ps2阴性者及C-erb2过表达者与非过表达者相比P均>0.05。结论乳腺癌组织中ER、PR表达与NACT疗效相关,Ps2、C-erbB-2表达与NACT疗效无关。ER、PR阴性的乳腺癌患者对化疗更敏感。Objective To investigate the relationship between the expression of ER,PR,Ps2 and Her-2 and the of neoadjuvant chemotherapy in breast cancer.Methods Immunohistochemical method was used to detect the expression of ER,PR,Ps2 and C-erb2 in 50 breast cancer which received neoadjuvant chemotherapy.Results The effective rates in ER negative and PR negative groups were higher than those in ER positive and PR positive groups（83.3% vs 59.4%、82.4%vs 60.6%）;There was no significant difference of the effective rate between Her-2 overexpressed group and Her-2 non-overexpressed group（81.8% vs 64.1%）,and the same thing happen between Ps2 negative group and Ps2 positive group（67.7% vs 63.2%）.Conclusions In the patients with breast cancer,ER 、PR negative ones are more sensitive to neoadjuvant chemotherapy.These patients may get more benefits from chemotherapy.ER,PR can be considered as predictive markers of the effective rate of neoadjuvant chemotherapy.

关 键 词：乳腺肿瘤 乳腺癌 新辅助化疗 雌激素受体 孕激素受体 雌激素调节蛋白 C-ERBB-2蛋白 

分 类 号：R737.9[医药卫生—肿瘤]